Add to balance / Manage account | User: | Log out |
Prospect News home > News index > List of issuers C > Headlines for Collagenex Pharmaceuticals, Inc. > News item |
CollaGenex reiterated at outperform by RBC
RBC Capital Markets analyst Ken Trbovich reiterated CollaGenex Pharmaceuticals Inc. at outperform, speculative risk, with a $19 price target. Oracea is expected to beat the analyst's August prescription estimate of 3,000, since the current run rate of 8,640 prescriptions also beats RBC's 8,000 monthly estimate for September. The RBC model forescasts Oracea reaching about 6,500 prescriptions per week by December. Shares of the Newtown, Pa.-based specialty pharmaceutical company were up 5 cents, or 0.42%, at $11.88, on volume of 104,623 shares versus the three-month running average of 230,115 shares. (Nasdaq: CGPI)
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.